|
|
|
|
| LEADER |
00000cam a22000007a 4500 |
| 001 |
SCIDIR_on1391440884 |
| 003 |
OCoLC |
| 005 |
20231120010748.0 |
| 006 |
m o d |
| 007 |
cr cnu|||||||| |
| 008 |
230729s2023 cau o 000 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|c EBLCP
|d YDX
|d OPELS
|d OCLCO
|d OCLCF
|
| 019 |
|
|
|a 1391434359
|
| 020 |
|
|
|a 9780323983488
|
| 020 |
|
|
|a 0323983480
|
| 020 |
|
|
|z 9780323917636
|
| 020 |
|
|
|z 0323917631
|
| 035 |
|
|
|a (OCoLC)1391440884
|z (OCoLC)1391434359
|
| 050 |
|
4 |
|a RM301.63
|
| 082 |
0 |
4 |
|a 615.6
|
| 245 |
0 |
0 |
|a Nanotechnology Principles in Drug Targeting and Diagnosis /
|c edited by Mahendra Rai, Shagufta Khan, Aarti Belgamwar.
|
| 260 |
|
|
|a San Diego :
|b Elsevier,
|c 2023.
|
| 300 |
|
|
|a 1 online resource (470 p.).
|
| 490 |
1 |
|
|a Micro and Nano Technologies
|
| 500 |
|
|
|a Description based upon print version of record.
|
| 505 |
0 |
|
|a Front Cover -- Nanotechnology Principles in Drug Targeting and Diagnosis -- Copyright Page -- Contents -- List of contributors -- Preface -- 1 Drug targeting: general principles and strategies -- 1 Drug targeting: nanotechnology principles, future perspectives, and challenges -- 1.1 Introduction -- 1.2 Nanotechnology-based drug targeting approaches -- 1.2.1 Passive targeting -- 1.2.2 Active targeting -- 1.2.3 Physical targeting -- 1.3 Targeted nanoparticulate systems for various disorders -- 1.3.1 Nanotechnology in cancer -- 1.3.2 Nanotechnology in infectious diseases
|
| 505 |
8 |
|
|a 1.3.3 Nanotechnology in cardiovascular diseases -- 1.3.4 Nanotechnology in autoimmune diseases -- 1.3.5 Nanotechnology in neurodegenerative diseases -- 1.3.6 Nanotechnology in respiratory diseases -- 1.3.7 Nanotechnology in ocular diseases -- 1.3.8 Application of artificial intelligence in targeted drug delivery -- 1.4 Future perspectives and challenges -- 1.5. Conclusion -- Acknowledgment -- References -- 2 Identifying nanocarrier-target interaction -- 2.1 Introduction -- 2.2 Potential targets for active targeting -- 2.2.1 Transferrin receptors -- 2.2.2 Human epidermal growth factor receptor 2
|
| 505 |
8 |
|
|a 2.2.3 CD19 -- 2.2.4 CD20 -- 2.2.5 Alpha beta 3 integrins -- 2.2.6 Luteinizing hormone-releasing hormone receptor -- 2.2.7 Folate -- 2.3 Surface modification strategies of nanocarriers -- 2.3.1 Tf-functionalized nanocarriers -- 2.3.2 Epidermal growth factor receptor-functionalized nanocarriers -- 2.3.3 CD19-functionalized nanocarriers -- 2.3.4 CD20-targeted nanocarriers -- 2.3.5 Alpha beta 3 integrin-targeted nanocarriers -- 2.3.6 Folate receptor-targeted nanocarriers -- 2.3.7 Luteinizing hormone-releasing hormone peptide-tagged nanocarriers -- 2.4 Factors affecting nanocarrier-cell interaction
|
| 505 |
8 |
|
|a 2.5 Methods to confirm carrier target interaction -- 2.5.1 Fluorescence microscopy -- 2.5.2 Raman imaging -- 2.5.3 Coherent anti-stokes Raman scattering microscopy -- 2.5.4 Electron microscopy -- 2.5.5 Correlative light-electron microscopy -- 2.6 Conclusion and future perspectives -- References -- 3 Artificial neural network-based inference of drug-target interactions -- 3.1 Introduction -- 3.1.1 Drug discovery and development process -- 3.1.1.1 Brief introduction -- 3.1.1.2 Research and development and attrition rates -- 3.2 Artificial neural networks -- 3.2.1 Principle and topology
|
| 505 |
8 |
|
|a 3.2.2 Basic topology -- 3.2.3 Machine learning -- 3.2.3.1 Learning algorithms -- 3.2.3.2 Deep learning -- Convolutional neural networks -- Recurrent neural networks -- Graph neural networks -- 3.3 Applications of artificial neural networks to drug-target interactions -- 3.3.1 Target identification and validation -- 3.3.2 Target compound synthesis -- 3.3.3 Drug designing -- 3.3.4 Drug pathway -- 3.3.5 Protein-ligand affinity -- 3.3.6 Pharmacological activities -- 3.3.7 Structure-activity relationship -- 3.3.8 Drug repurposing -- 3.3.9 Drug-drug interactions -- 3.3.9.1 Synergistic effect
|
| 500 |
|
|
|a 3.3.9.2 Pharmacological action
|
| 650 |
|
0 |
|a Drug targeting.
|
| 650 |
|
0 |
|a Nanotechnology
|x Therapeutic use.
|
| 650 |
|
2 |
|a Drug Delivery Systems
|0 (DNLM)D016503
|
| 650 |
|
6 |
|a M�edicaments
|x Ciblage.
|0 (CaQQLa)201-0196695
|
| 650 |
|
6 |
|a Nanotechnologie
|0 (CaQQLa)201-0225435
|x Emploi en th�erapeutique.
|0 (CaQQLa)201-0373975
|
| 650 |
|
7 |
|a Drug targeting.
|2 fast
|0 (OCoLC)fst00898709
|
| 700 |
1 |
|
|a Rai, Mahendra.
|
| 700 |
1 |
|
|a Khan, Shagufta.
|
| 700 |
1 |
|
|a Belgamwar, Aarti.
|
| 776 |
0 |
8 |
|i Print version:
|a Rai, Mahendra
|t Nanotechnology Principles in Drug Targeting and Diagnosis
|d San Diego : Elsevier Science & Technology,c2023
|z 9780323917636
|
| 776 |
0 |
8 |
|i Print version:
|t NANOTECHNOLOGY PRINCIPLES IN DRUG TARGETING AND DIAGNOSIS.
|d [S.l.] : ELSEVIER, 2023
|z 0323917631
|w (OCoLC)1333079926
|
| 830 |
|
0 |
|a Micro & nano technologies.
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780323917636
|z Texto completo
|
